Results 141 to 150 of about 25,411 (262)

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?

Journal of the Formosan Medical Association
Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that,
Jin-Ying Lu, Yi-Yao Chang, Ting-Wei Lee, Ming-Hsien Wu, Zheng-Wei Chen, Yen-Ta Huang, Tai-Shuan Lai, Leay Kiaw Er, Yen-Hung Lin, Vin-Cent Wu, Hao-Min Cheng, Hsien-Li Kao, Charles Jia-Yin Hou, Kwan-Dun Wu, Szu-Tah Chen, Feng-Hsuan Liu   +15 more
doaj   +1 more source

Phenotyping of acute heart failure with preserved ejection fraction: real‐world outcomes in a cohort of older patients

Internal Medicine Journal, EarlyView.
Abstract Background Previous studies have identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). Aims This study aims to identify distinct phenotypes in older patients with HFpEF hospitalised for acute heart failure (AHF) and investigate the relationship between subgroups and outcomes ...
Maria Livia Burzo *, Giuseppe De Matteis, Amato Serra, Davide Antonio Della Polla, Mariella Fuorlo, Maria Anna Nicolazzi, Benedetta Simeoni, Antonio Gasbarrini, Francesco Franceschi, Giovanni Gambassi, Marcello Covino   +10 more
wiley   +1 more source

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Терапевтический архив, 2015
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials.
Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko   +2 more
doaj  

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

Journal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Masahiro Sugawara, Hiroaki Satoh, Yukiko Sugawara, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +10 more
wiley   +1 more source

Mechanisms of hesperetin in alleviating diabetic nephropathy: Network pharmacology, molecular docking, and experimental validation

Journal of Diabetes Investigation, EarlyView.
Hesperetin increases cell viability and reduces cell apoptosis, ferroptosis, release of inflammatory cytokines, and oxidative stress of human kidney tubular cells via repressing IGF1R expression. ABSTRACT Background Diabetic nephropathy (DN) accounts for approximately 50% of chronic kidney disease cases.
Yiwen Guo, Fengjiao Zhang, Yu Jin, Menglu Zhu, Zhiqiang Kang   +4 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden.
Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Wenbin Gao, Austin Todd, Joseph J. Maleszewski, Francis D. Pagani, Hartzell Schaff, Y. Eugene Chen, Paul A. Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C. Tang   +18 more
doaj   +1 more source

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

Integrated Blood Pressure Control, 2013
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone was shown to be an extraordinarily effective ...
openaire   +4 more sources